Search results for "prognosis."

showing 10 items of 2044 documents

Professional diagnostic delay in osteosarcomas of the jaws

2020

A series of 20 consecutive patients with an osteosarcoma of the jaws has been evaluated with regard to possible professional diagnostic delay. When set at an arbitrarily chosen period beyond three months, professional delay occurred in 15 patients, the mean being 21 months and the median 11 months. In five of the 15 patients a wrong diagnosis has been rendered on the biopsy specimen, being fibrous dysplasia (2x), osteoma (2x) and, in case of palatomaxillary swelling, pleomorphic adenoma (1x). In the other ten patients the initial clinicoradiographic features were misleading and apparently not indicative of a malignancy, except for one patient in whom a distinct widening of the periodontal l…

medicine.medical_specialtyDelayed DiagnosisBone NeoplasmsDelayed diagnosisMalignancyPleomorphic adenoma03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingBiopsymedicineHumansGeneral DentistryOsteomaOsteosarcomamedicine.diagnostic_testbusiness.industryResearchFibrous dysplasia030206 dentistryPrognosisMedically compromised patients in Dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseOtorhinolaryngologyUNESCO::CIENCIAS MÉDICAS/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingOsteosarcomaSurgeryRadiologybusiness
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Subclinical atrial fibrillation: how hard should we look?

2012

More than three decades ago, an analysis from the Framingham Heart Study revealed that atrial fibrillation (AF) increases the risk of stroke by a factor of five in non-rheumatic AF and by a factor of 17 in rheumatic AF.1 Since then, it has convincingly been shown that anticoagulation is one of the most effective secondary stroke prophylactic treatment options, which reduces the risk of stroke by 2/3,2 even in an older population.3 AF may occur in different types and in an individual patient often starts with paroxysmal AF, but later becomes persistent or permanent AF.4 Interestingly, the risk of stroke or systemic embolism is influenced by cardiovascular risk factors such as hypertension, d…

medicine.medical_specialtyDisease030204 cardiovascular system & hematologyGlobal HealthAsymptomatic03 medical and health sciences0302 clinical medicineFramingham Heart StudyRisk FactorsInternal medicineAtrial FibrillationmedicineHumansClinical significancecardiovascular diseasesStrokeSubclinical infectionAgedbusiness.industryIncidenceCardiac Pacing ArtificialAnticoagulantsAtrial fibrillationmedicine.diseasePrognosis3. Good healthStrokeCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryAtrial flutterHeart (British Cardiac Society)
researchProduct

Infective endocarditis triangle.. Is it the time to revisit infective endocarditis susceptibility and indications for its antibiotic prophylaxis?

2019

medicine.medical_specialtyEndocarditisEpidemiologybusiness.industryMEDLINEAntibiotic ProphylaxisGlobal HealthPrognosismedicine.diseaseAnti-Bacterial AgentsSurvival RateBacterial endocarditisInfective endocarditismedicineHumansAntibiotic prophylaxisCardiology and Cardiovascular MedicinebusinessIntensive care medicineEuropean Journal of Preventive Cardiology
researchProduct

Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction

2008

Endothelial dysfunction (ED) in the setting of cardiovascular risk factors such as hypercholesterolemia, hypertension, diabetes mellitus, chronic smoking as well as in patients with heart failure has been shown to be at least in part dependent on the production of reactive oxygen species (ROS) such as superoxide and the subsequent decrease in vascular bioavailability of nitric oxide (NO). Methods to quantify endothelial dysfunction include forearm plethysmography, flow-dependent dilation of the brachial artery, finger-pulse plethysmography, pulse curve analysis, and quantitative coronary angiography after intracoronary administration of the endothelium-dependent vasodilator acetylcholine. S…

medicine.medical_specialtyEndotheliumPathogenesisRisk FactorsDiabetes mellitusInternal medicinemedicineAnimalsHumansEndothelial dysfunctionClinical Trials as Topicbusiness.industrynutritional and metabolic diseasesGeneral MedicinePrognosismedicine.diseaseAscorbic acidPathophysiologyPrimary PreventionEndothelial stem cellOxidative StressEndocrinologymedicine.anatomical_structureCardiovascular DiseasesHeart failureCardiologyEndothelium VascularReactive Oxygen SpeciesbusinessBiomarkersAnnals of Medicine
researchProduct

Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.

2014

What is known and objective: Pemphigus is a severe, potentially life-threatening autoimmune blistering disease. The use of corticosteroids has dramatically improved the prognosis and changed its course. However, current morbidity of pemphigus is largely iatrogenic, caused by side effects of the long-term, high-dose corticosteroid therapy that is necessary to sustain disease control. In order to minimize side effects, a range of corticosteroid-sparing immunosuppressive agents have been introduced, including mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS). A systematic review was performed to evaluate the effectiveness of MMF and EC-MPS in the treatment of pemphig…

medicine.medical_specialtyEnteric-coated mycophenolate sodium mycophenolate mofetil mycophenolic acid pemphigus foliaceus pemphigus vulgaris therapyDermatologyMycophenolateMycophenolic acidimmune system diseasesmedicineSettore MED/35 - Malattie Cutanee E VenereeHumansEnteric coatedskin and connective tissue diseasesGlucocorticoidsPemphigus foliaceusintegumentary systembusiness.industryPemphigus vulgarisMycophenolate SodiumMycophenolic AcidPrognosismedicine.diseaseDermatologyPemphigusTreatment OutcomeDrug Therapy CombinationDermatologic AgentsbusinessImmunosuppressive AgentsPemphigusmedicine.drugBlistering disease
researchProduct

Epidemiology and risk factors for oesophageal adenocarcinoma.

2013

Oesophageal adenocarcinoma will soon cease to be a rare form of cancer for people born after 1940. In many Western countries, its incidence has increased more rapidly than other digestive cancers. Incidence started increasing in the Seventies in England and USA, 15 years later in Western Europe and Australia. The cumulative risk between the ages of 15 and 74 is particularly striking in the UK, with a tenfold increase in men and fivefold increase in women in little more than a single generation. Prognosis is poor with a 5-year relative survival rate of less than 10%. The main known risk factors are gastro-oesophageal reflux, obesity (predominantly mediated by intra-abdominal adipose tissues)…

medicine.medical_specialtyEsophageal NeoplasmsPopulationOesophageal adenocarcinomaAdenocarcinomaGlobal HealthGastroenterologyBody Mass IndexBarrett EsophagusAge DistributionRisk FactorsInternal medicineEpidemiologymedicineRelative survival rateHumansSex Distributioneducationeducation.field_of_studyHepatologybusiness.industryIncidence (epidemiology)IncidenceSmokingGastroenterologyCancermedicine.diseasePrognosisObesitydigestive system diseasesSurvival RateObesity AbdominalGastroesophageal RefluxAdenocarcinomabusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Fully robotic Ivor–Lewis esophagectomy (RAMIE4) for esophageal cancer after emergency surgery and ligation of the gastroduodenal artery

2018

We report a case of a 69-year-old patient with esophageal cancer and severe upper gastrointestinal bleeding during neoadjuvant radiochemotherapy who required mass transfusion followed by complex emergency procedures. Despite endoscopic stenting, the bleeding recurred, and thus emergency open surgery was required. Gastric wedge resection of the minor curvature necessitated by perforation caused by the endoscopic stent maneuver and duodenotomy with ligation of the gastroduodenal artery, as the cause of persistent intraluminal bleeding, were performed. The already prepared gastric conduit during the emergency operation did not become ischemic, even though the gastroduodenal artery, left gastr…

medicine.medical_specialtyGastrointestinal bleedingMedicine (General)Esophageal NeoplasmsDuodenumgastrointestinal bleedingHemorrhagereal-time fluoroscopyCase Reports030204 cardiovascular system & hematologyAdenocarcinomaBiochemistryIvor–Lewis esophagectomyGastroduodenal artery03 medical and health sciences0302 clinical medicineR5-920Emergency surgeryRobotic Surgical Proceduresmedicine.arteryMedicineIvor lewisHumansRobotic surgeryesophageal cancerAgedbusiness.industryBiochemistry (medical)Robotic surgeryCell BiologyGeneral MedicineArteriesChemoradiotherapy AdjuvantEsophageal cancermedicine.diseasePrognosisNeoadjuvant TherapySurgeryEsophagectomy030220 oncology & carcinogenesisgastric conduitUpper gastrointestinal bleedingbusinessLigationJournal of International Medical Research
researchProduct

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

2019

Knowledge of genetic susceptibility to gastrointestinal cancers is constantly evolving with identification of new genes. Similarly, a better understanding of the genotype/phenotype relationship in patients with Lynch syndrome (LS) or familial adenomatous polyposis (FAP) is leading to more individualised surveillance recommendations. In addition, molecular profiling of patients with cancer has been shown to guide targeted therapies, such as immunotherapy. Specialists involved in the care of patients with gastrointestinal cancer should be familiar with the main hereditary cancer syndromes and refer patients to specialised cancer genetic units for adequate genetic counselling and to address sp…

medicine.medical_specialtyHealth Planning Guidelinesbusiness.industryMEDLINEHematologyPrognosisCombined Modality TherapyClinical PracticeText miningOncologyDiagnosis treatmentPractice Guidelines as TopicmedicineMolecular diagnostic techniquesHumansGenetic Predisposition to DiseasebusinessIntensive care medicineSocieties MedicalFollow-Up StudiesGastrointestinal Neoplasms
researchProduct

Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-E…

2021

Background: Retrospective analyses of clinical trials indicate that elevated serum uric acid (sUA) predicts poor outcome in heart failure (HF). Uric acid can contribute to inflammation and microvascular dysfunction, which may differently affect different left ventricular ejection fraction (LVEF) phenotypes. However, role of sUA across LVEF phenotypes is unknown. Objectives: We investigated sUA association with outcome in a prospective cohort of HF patients stratified according to LVEF. Methods: Through the Heart Failure Long-Term Registry of the European Society of Cardiology (ESC-EORP-HFLT), 4,438 outpatients were identified and classified into: reduced (= 50% HFpEF) LVEF. Endpoints were t…

medicine.medical_specialtyHeart failure030204 cardiovascular system & hematologyVentricular Function Left03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineInternal MedicinemedicineHumansIn patient030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyRetrospective StudiesInflammationEjection fractionbusiness.industryStroke Volumemedicine.diseasePrognosisClinical trialPhenotypechemistryQuartileHeart failureCohortCardiologyUric acidbusinessUric acid
researchProduct